Growing knowledge of the diseases in the nervous system combined with new gains in gene technology make the timing right for a dedicated and focused effort to develop new cell and gene based products for the treatment of neurological diseases. Biologics open a wide range of new ways to treat diseases and offer realistic hopes for the development of treatments of today incurable diseases. NsGene is with its unique proprietary factors and EC BiodeliveryTM platform an attractive and interesting partner for biotechnology or pharmaceutical companies developing therapies for the treatment of neurological diseases.
NsGene presents a number of interesting partnering opportunities within its R&D programs. NsGene seeks collaboration partners to develop, market, and sell EC BiodeliveryTM products for Alzheimer’s disease (NsG0202) and Parkinson's disease. In addition, NsGene seeks partners to develop EC BiodeliveryTM products as a delivery technology platform for other neurological diseases. With regard to factor products, NsGene seeks partners to commercialise the applications of NsG33 (Meteorin) for neuropathic pain.
